Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04655872
Other study ID # TPN171H-07
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 26, 2020
Est. completion date January 27, 2021

Study information

Verified date November 2020
Source Vigonvita Life Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is objective to evaluate the in vivo absorption, excretion and biotransformation pathways of [14C]-TPN171H in Chinese male healthy volunteers, and to reveal the overall pharmacokinetic characteristics of TPN171H in human body, so as to provide basis for rational use of the drug.


Description:

This will be an open-label, single-center study to evaluate the mass-balance and pharmacokinetics of TPN171H in approximately 6 healthy male subjects receiving a single oral 10 mg dose of TPN171H containing approximately 100 microcuries of [14C]-TPN171H. Subjects will be checked in to the research unit from approximately 24 hours prior to dosing and remain in house until greater than 80% of the administered radioactivity is collected from bodily excreta or until less than 1% of the administered radioactivity is recovered from excreta in two consecutive time intervals, and blood sample radioactivity concentration at two consecutive time points less than 3 times the plasma background value. This study will investigate the main biotransformation and elimination pathways of TPN171H in the human body and will seek to identify compound's major metabolites.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date January 27, 2021
Est. primary completion date January 27, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Healthy male subjects between the ages of 19 and 55 years,with normal bowel movements (1~2 times a day); - Body Mass Index of 19 to 26 kg/m2; Body weight no less than 50 kg; - Physical examination, vital signs examination, laboratory examination (blood routine, urine routine, blood biochemistry, thyroid function, stool routine and occult blood, etc.), 12 lead ECG, B-ultrasound, chest X-ray and fundus examination results were normal or abnormal without clinical significance; - The male subjects with fertility had no child rearing plan or sperm donation plan with their sexual partners during the trial and within one year after taking the drug, and could take reliable contraceptive measures; - Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent, and can complete the whole trial process according to the test requirements. Exclusion Criteria: - People with allergies or allergic diseases, or known allergies to test preparations, any of their ingredients, and related preparations; - There are clear diseases of the central nervous system, cardiovascular system, digestive system (including those with severe fatty liver in B-ultrasound examination), respiratory system, urinary system, blood system, metabolic disorders, etc. and require medical intervention or other unsuitable clinical trials Those with tested diseases (such as history of mental illness, etc.); those with a history of orthostatic hypotension; - Blurred vision or a history of the following ocular diseases: nonvascular anterior ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinal degeneration (such as retinitis pigmentosa), macular degeneration; - Any drug that inhibits or induces liver drug-metabolizing enzymes (inducers-barbiturates, carbamazepine, phenytoin, rifampicin, dexamethasone, rifabutin, rifapentine) has been used within 30 days before administration ; Inhibitors-SSRI antidepressants, cimetidine, diltiazem, macrolides, verapamil, imidazole antifungals, sedatives and hypnotics, fluoroquinolones, antihistamines, etc.); - Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health care products within 2 weeks before administration; or those who have participated in other drug clinical trials and received trial drugs within 3 months before administration; - Those who have a history of drug dependence (including a history of drug use) within 2 years before administration; or urine drug abuse screening (morphine, tetrahydrocannabinol acid, methamphetamine, dimethylene oxyamphetamine) , Ketamine and cocaine) positive; - Those who smoke more than 10 cigarettes per day and do not agree to avoid using any tobacco products during the trial period; - Positive results of alcohol breath test, or current/previous alcoholics (drinking more than 21 standard units per week. 1 standard unit contains 14 g of alcohol, such as 360 mL of beer or 45 mL of 40% spirits or 150 mL wine); - People who have consumed excessive amounts of grapefruit juice, tea, coffee and/or caffeinated beverages for a long time (more than 8 cups a day, 1 cup equal to 250 mL); - Those who are positive for hepatitis B surface antigen (HBsAg), HCV antibody, syphilis antibody and HIV antibody; - Blood loss or blood donation of 400 mL or more within 3 months before administration; - Those who have been vaccinated within 6 months before administration; - A history of fainting needles or fainting blood; - Hemorrhoids or perianal diseases with regular/current stools; habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease; - Workers who need to be exposed to radioactive conditions for a long time; or have significant radioactive exposure more than 2 chest/abdominal CT, or more than 3 other types of X-ray examinations) within 1 year before administration or participated in radiopharmaceutical labeling Experimenter - The investigator believes that there are other factors that are not suitable for participating in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[14C]TPN171H
A single 10 mg oral dose of [14C]TPN171H containing approximately 100 microcurie of [14C]-TPN171H.

Locations

Country Name City State
China Shanghai Xuhui Central Hospital Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Vigonvita Life Sciences Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax - maximum observed plasma concentration From time zero up to 336 hours post-dose following oral administration of [14C]TPN171H
Primary Tmax - time at which Cmax occurs From time zero up to 336 hours post-dose following oral administration of [14C]TPN171H
Primary AUC0~t - area under the plasma concentration time curve from time zero to the last measurable concentration From time zero up to 336 hours post-dose following oral administration of [14C]TPN171H
Primary AUC0-8 - area under the plasma concentration-time curve from time zero to infinity From time zero up to 336 hours post-dose following oral administration of [14C]TPN171H
Primary Total radioactivity in urine and faeces From time zero up to 336 hours post-dose following oral administration of [14C]TPN171H
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT04839744 - A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT03576651 - A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1
Completed NCT04850638 - Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) Phase 1